{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG000","lowerLimit":"2.2","upperLimit":"NA","value":"10.0"},{"comment":"Upper limit of 95% CI was not estimable as there were less number of participants with an event.","groupId":"OG001","lowerLimit":"2.0","upperLimit":"NA","value":"11.7"},{"groupId":"OG002","lowerLimit":"3.0","upperLimit":"7.9","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"OS was defined as the time (in months) from the date of first dose of study drug to the date of death due to any cause or data censoring date, whichever occurred first. Participants last known to be alive were censored at the date of last contact. OS was analyzed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 sub-cutaneous \\[SC\\] administered at weekly intervals, followed by 5 intra tumoral \\[IT\\] administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W. Phase 2 was not planned.","id":"OG000","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg + Avelumab"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 SC administered at weekly intervals, followed by 5 IT administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W all cohorts plus utomilumab 100 mg administered IV Q4W. Phase 2 was not planned.","id":"OG001","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg Then Avelumab + Utomilumab 100 mg"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 SC administered at weekly intervals, followed by 5 IT administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W all cohorts plus PF-04518600 at 0.3 mg/kg administered IV Q2W. Phase 2 was not planned.","id":"OG002","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg Then Avelumab + PF-04518600 0.3 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug to date of death from any cause or data censoring date, whichever occurred first (maximum up to 7.3 years)","title":"OS for Combination F","type":"SECONDARY","unitOfMeasure":"Months"}